ES2952332T3 - Compuestos espirocíclicos y sus métodos de preparación y uso - Google Patents

Compuestos espirocíclicos y sus métodos de preparación y uso Download PDF

Info

Publication number
ES2952332T3
ES2952332T3 ES18850498T ES18850498T ES2952332T3 ES 2952332 T3 ES2952332 T3 ES 2952332T3 ES 18850498 T ES18850498 T ES 18850498T ES 18850498 T ES18850498 T ES 18850498T ES 2952332 T3 ES2952332 T3 ES 2952332T3
Authority
ES
Spain
Prior art keywords
compound
pharmaceutically acceptable
formula
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18850498T
Other languages
English (en)
Spanish (es)
Inventor
Cheryl A Grice
Olivia D Weber
Daniel J Buzard
Michael B Shaghafi
Todd K Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Application granted granted Critical
Publication of ES2952332T3 publication Critical patent/ES2952332T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
ES18850498T 2017-08-29 2018-08-28 Compuestos espirocíclicos y sus métodos de preparación y uso Active ES2952332T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29
PCT/US2018/048372 WO2019046318A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
ES2952332T3 true ES2952332T3 (es) 2023-10-30

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18850498T Active ES2952332T3 (es) 2017-08-29 2018-08-28 Compuestos espirocíclicos y sus métodos de preparación y uso

Country Status (27)

Country Link
US (1) US11142526B2 (https=)
EP (1) EP3675847B1 (https=)
JP (1) JP7257387B2 (https=)
KR (1) KR20200046061A (https=)
CN (1) CN111050765B (https=)
AU (1) AU2018323459A1 (https=)
BR (1) BR112020004101A2 (https=)
CA (1) CA3072923A1 (https=)
CL (1) CL2020000462A1 (https=)
CO (1) CO2020001724A2 (https=)
CR (1) CR20200089A (https=)
DO (1) DOP2020000039A (https=)
EA (1) EA202090312A1 (https=)
EC (1) ECSP20013337A (https=)
ES (1) ES2952332T3 (https=)
GE (2) GEAP202115281A (https=)
IL (1) IL272580B (https=)
JO (1) JOP20200023A1 (https=)
MA (1) MA50041A (https=)
MX (1) MX2020002251A (https=)
NI (1) NI202000014A (https=)
PE (1) PE20200664A1 (https=)
PH (1) PH12020500372A1 (https=)
SG (1) SG11202001022TA (https=)
UA (1) UA126685C2 (https=)
WO (1) WO2019046318A1 (https=)
ZA (1) ZA202001208B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN111032034B (zh) 2017-08-29 2023-05-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
BR112021026899A2 (pt) * 2019-07-09 2022-05-10 Hoffmann La Roche Compostos heterocíclicos
WO2022043284A1 (en) * 2020-08-26 2022-03-03 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as magl inhibitors
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト,インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8575296B2 (en) 2009-09-29 2013-11-05 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2011109277A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
JP2018513119A (ja) * 2015-03-18 2018-05-24 アビデ セラピューティクス,インク. ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA124884C2 (uk) 2016-11-16 2021-12-08 Лундбек Ла Джолла Ресеарч Центер, Інк. Фармацевтичні склади
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN111032034B (zh) 2017-08-29 2023-05-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法

Also Published As

Publication number Publication date
IL272580B (en) 2022-09-01
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
CR20200089A (es) 2020-04-08
EP3675847A1 (en) 2020-07-08
PE20200664A1 (es) 2020-06-11
JP7257387B2 (ja) 2023-04-13
ECSP20013337A (es) 2020-04-22
PH12020500372A1 (en) 2020-12-07
EP3675847B1 (en) 2023-07-12
RU2020107163A (ru) 2021-09-30
AU2018323459A1 (en) 2020-02-20
CN111050765A (zh) 2020-04-21
EA202090312A1 (ru) 2020-08-05
US11142526B2 (en) 2021-10-12
MA50041A (fr) 2020-07-08
US20200255427A1 (en) 2020-08-13
BR112020004101A2 (pt) 2020-09-24
RU2020107163A3 (https=) 2022-03-15
SG11202001022TA (en) 2020-03-30
EP3675847A4 (en) 2021-01-06
GEP20217327B (en) 2021-12-10
CN111050765B (zh) 2024-01-02
DOP2020000039A (es) 2020-08-31
UA126685C2 (uk) 2023-01-11
IL272580A (en) 2020-03-31
WO2019046318A1 (en) 2019-03-07
ZA202001208B (en) 2021-08-25
GEAP202115281A (en) 2021-08-10
CA3072923A1 (en) 2019-03-07
EP3675847C0 (en) 2023-07-12
JOP20200023A1 (ar) 2020-02-02
JP2020532545A (ja) 2020-11-12
KR20200046061A (ko) 2020-05-06
CL2020000462A1 (es) 2020-07-10
CO2020001724A2 (es) 2020-02-28

Similar Documents

Publication Publication Date Title
ES2952332T3 (es) Compuestos espirocíclicos y sus métodos de preparación y uso
ES2914363T3 (es) Compuestos espirocíclicos y métodos para su preparación y uso
BR112020026534A2 (pt) Compostos de heteroarila para o tratamento da doença de huntington
EP3145929B1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
ES2761332T3 (es) Compuestos y composiciones como inhibidores de la cinasa c-kit
ES3005265T3 (en) Pyrazole magl inhibitors
JP6647592B2 (ja) ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
ES2822979T3 (es) Derivados de pirazol, procesos para su preparación, y sus usos
ES2892952T3 (es) Carbamatos de piperazina como moduladores del MAGL y/o ABHD6 y su uso
JP6437452B2 (ja) Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
US9822124B2 (en) Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
HUE028723T2 (en) Piperidin-4-yl azetidine derivatives as JAK-1 inhibitors
JP2016528298A (ja) Pimキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
JP2019530740A (ja) ピリジン並びに5員芳香環系化合物、その製造方法及び使用
CN107428756B (zh) 6-吗啉基-2-吡唑基-9h-嘌呤衍生物及其作为pi3k抑制剂的用途
JP7473544B2 (ja) アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
RU2781639C2 (ru) Спироциклические соединения и способы их получения и применения
HK40032869A (en) Spirocycle compounds and methods of making and using same
HK40032869B (en) Spirocycle compounds and methods of making and using same
EA041386B1 (ru) Спироциклические соединения и способы их получения и применения
GB2558975A (en) New compounds